Oct 03, 2019
Zydus Announces Positive Results From EVIDENCES IV Phase 2 Clinical Trial of Saroglitazar Magnesium in NAFLD and NASH
Sep 26, 2019
Galmed Pharmaceuticals Initiated ARMOR, a Phase 3/4 Registrational Study of Aramchol in Subjects With NASH and Fibrosis
Sep 25, 2019
89bio Announces Dosing of First Patients in NASH Study and Issuance of Composition of Matter Patent
Sep 24, 2019
PharmaNest Launches FibroNest, the First Multivendor Image Analysis and Translational Platform for the Assessment of the Severity and Progression of Fibrosis in NASH
Sep 17, 2019
DURECT Announces Positive Data from its Phase 2a Clinical Trial of DUR-928 in Alcoholic Hepatitis
Aug 28, 2019
FDA In Brief: FDA warns patients and health care professionals about rare instances of serious liver injury or failure with certain hepatitis C treatments in some patients with advanced liver disease
Aug 27, 2019
Ascletis Received IND Approval for its NASH Drug
Aug 27, 2019
Ionis licenses hepatitis B program to GSK
Aug 12, 2019
Ascletis Opens Clinical Development Shanghai Center
Aug 12, 2019
Strategic in-licensing Related to Autoimmune Hepatitis in the US Market
Aug 08, 2019
Laboratory for Advanced Medicine Strengthens Hepatology Board with Addition of Three Distinguished Medical Doctors
Aug 08, 2019
89bio Initiates Phase 1b/2a Proof of Concept Clinical Trial of Investigational Therapy BIO89-100 for the Treatment of NASH
Aug 05, 2019
3-V Biosciences Changes Name to Sagimet Biosciences and Closes $25 Million Financing
Aug 04, 2019
Ascletis Received IND Approval and Management Outlook of 2019 and Beyond
Aug 01, 2019
DURECT Corporation Announces Second Quarter 2019 Financial Results and Update of Programs
Jul 29, 2019
Galmed Pharmaceuticals to Report Second Quarter 2019 Financial Results and Provide Business Update on Monday, August 5
Jul 11, 2019
Hepatitis B in the United States: In-depth Market Analysis 2014-2019 and Forecast to 2024
Jul 08, 2019
The global alcoholic hepatitis treatment market at a CAGR of close to 6% during the forecast period
Jul 08, 2019
Intent Solutions Joins University of Kentucky Program to Eliminate Hepatitis C in Appalachia
Jul 02, 2019
HighTide Therapeutics Expands Leadership Team with Appointment of Adrian M. Di Bisceglie, M.D., as Chief Medical Officer